GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » Dividend Payout Ratio

URGN (UroGen Pharma) Dividend Payout Ratio : 0.00 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. UroGen Pharma's Dividend Payout Ratio for the months ended in Sep. 2024 was 0.00.

The historical rank and industry rank for UroGen Pharma's Dividend Payout Ratio or its related term are showing as below:


URGN's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.48
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-12-14), the Dividend Yield % of UroGen Pharma is 0.00%.

UroGen Pharma's Dividends per Share for the months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


UroGen Pharma Dividend Payout Ratio Historical Data

The historical data trend for UroGen Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Dividend Payout Ratio Chart

UroGen Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only - - - - -

UroGen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of UroGen Pharma's Dividend Payout Ratio

For the Biotechnology subindustry, UroGen Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Dividend Payout Ratio falls into.



UroGen Pharma Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

UroGen Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2023 )/ EPS without NRI (A: Dec. 2023 )
=0/ -2.96
=N/A

UroGen Pharma's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Sep. 2024 )/ EPS without NRI (Q: Sep. 2024 )
=0/ -0.442
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UroGen Pharma (NAS:URGN) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


UroGen Pharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


UroGen Pharma Business Description

Traded in Other Exchanges
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Executives
Mark Schoenberg officer: Chief Medical Officer C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Jason Drew Smith officer: General Counsel C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Daniel George Wildman director 12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim officer: Chief Financial Officer C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett officer: Chief Executive Officer C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix officer: COO C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden director C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur director, officer: Chief Executive Officer 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102